Seelos Therapeutics Inc Stock Price, News & Analysis

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the 2021 Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company's Chairman and CEO, Raj Mehra, Ph.D., is scheduled to present on June 3rd at 10:30am ET and will also hold 1x1 meetings. Seelos focuses on developing novel therapeutics for central nervous system disorders and rare diseases, with key assets targeting serious conditions such as Major Depressive Disorder and Amyotrophic Lateral Sclerosis. Registration for the presentation can be found here.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has received a positive opinion for European Orphan Drug Designation for SLS-005 in treating amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA). The European Commission is expected to grant this designation within 30 days, which will provide Seelos with benefits like protocol assistance and market exclusivity. SLS-005 has also received Orphan Drug Designation from the FDA for ALS and other conditions, along with Fast Track designation for Oculopharyngeal Muscular Dystrophy (OPMD).

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the 2021 RBC Capital Markets Global Healthcare Conference from May 18-20, 2021. Chairman and CEO Raj Mehra, Ph.D., is set to present on May 18 at 4:50 PM ET and will host 1x1 meetings on May 18 and 19. The company is dedicated to developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Major Depressive Disorder, amyotrophic lateral sclerosis (ALS), and Sanfilippo syndrome. For further details, visit their website.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the B. Riley Securities' Neuroscience Conference on April 28-29, 2021. Chairman and CEO Raj Mehra, Ph.D., will present on April 28 at 11:00am ET. The conference will address critical topics in neurodegeneration, neuropsychiatry, and mental health, featuring various healthcare companies. Seelos focuses on developing therapies for CNS disorders and rare diseases, boasting a portfolio that includes clinical assets for Acute Suicidal Ideation and Behavior (ASIB), ALS, and Parkinson's disease.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has signed a Strategic Device Partnership with AptarGroup, Inc. (NYSE: ATR) for the co-exclusive use of Aptar Pharma's Bidose Liquid System to enhance the delivery of its intranasal ketamine candidate, SLS-002. This device is pivotal for treating suicidality, depression, and PTSD. Seelos has successfully completed part 1 of its Proof-of-Concept study involving 16 patients, and expects to share key data in Q2 2021. This partnership aims to optimize the franchise for SLS-002, addressing an urgent need for effective treatments in critical situations.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has completed patient enrollment for Part 1 of its Proof of Concept study of SLS-002 (intranasal ketamine) aimed at treating Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder. Results from Part 1, involving 16 participants, are anticipated in Q2 2021, following the last patient's completion on April 1, 2021. The company plans to expand the trial in Part 2, enrolling around 120 patients. This study addresses the significant unmet need in rapid depression treatment.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced an amendment to its agreement with Vyera Pharmaceuticals AG to repurchase a significant portion of the royalties from future sales of SLS-002, an intranasal ketamine therapy. This move reduces royalty obligations from mid-teens to a mid-single digit percentage, aimed at enhancing shareholder value. SLS-002 is currently being studied to treat major depressive disorder in patients at imminent risk of suicide. The company is optimistic about the clinical development and potential commercialization of this therapy.

Seelos Therapeutics (Nasdaq: SEEL) will participate in the 33rd Annual Roth Conference virtually from March 15-17, 2021. Chairman and CEO Raj Mehra, Ph.D., will conduct 1x1 meetings on March 16 and 17. The company focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio including treatments for conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson's disease. For more information, visit seelostherapeutics.com.

Seelos Therapeutics (Nasdaq: SEEL) announced the issuance of a new patent from the Australian Patent Office for its drug SLS-005, aimed at treating neurodegenerative diseases linked to protein aggregation. The patent covers a method of intravenous administration of trehalose to address conditions such as oculopharyngeal muscular dystrophy and spinocerebellar ataxia. Trehalose helps stabilize proteins and activates autophagy, potentially reducing the impact of misfolded proteins in cells, as demonstrated in animal studies.